Intravenous Immunoglobulin Market Size - Share Outlook, Growth Analysis Report and Forecast Trends 2026-2030

IVIG is a purified blood plasma product containing concentrated antibodies collected from thousands of donors, administered intravenously to patients with compromised immune systems. The therapy treats a broad spectrum of conditions including primary immunodeficiencies, immune thrombocytopenic purpura, Kawasaki disease, and neurological disorders such as chronic inflammatory demyelinating polyneuropathy and myasthenia gravis. With approximately $22.16 billion in global revenue in 2025, the market reflects sustained demand across both developed and emerging healthcare systems.

• •Primary applications include primary immunodeficiency diseases, autoimmune disorders, and neurological conditions
• •Market benefits from a well-established safety profile and decades of clinical use
• •Demand is reinforced by the lack of curative alternatives for many treated conditions

The expansion of approved indications beyond traditional immunological uses to neurological and hematological applications has significantly broadened the addressable patient population. Increasing prevalence of autoimmune diseases, coupled with improved diagnostic capabilities and greater physician awareness, continues to drive patient identification and treatment initiation. Additionally, growing healthcare expenditure in developing regions and expanding insurance coverage for biologic therapies support market penetration.

• •Rising incidence of primary and secondary immunodeficiency disorders globally
• •Off-label and newly approved uses in neurology and rheumatology expanding utilization
• •Limited competition from alternative biologic therapies maintaining IVIG's market position

The market segments by indication into primary immunodeficiency, secondary immunodeficiency, autoimmune and inflammatory disorders, and neurological applications, with primary immunodeficiency representing the largest category. North America dominates regional demand due to high disease prevalence, sophisticated diagnostic networks, and comprehensive reimbursement frameworks. Europe follows as the second-largest market, while Asia-Pacific emerges as the fastest-growing region attributable to rising healthcare investment, increasing disease awareness, and expanding plasma collection infrastructure in countries such as China and India.

• •North America accounts for approximately 40-45% of global market share
• •Asia-Pacific is projected to achieve above-average growth rates through expanding plasma fractionation capacity
• •Europe maintains strong market presence driven by universal healthcare coverage and established treatment protocols

What are the recent trends and outlook?

The market trajectory points toward sustained growth through 2030 and beyond, with projections suggesting continued expansion approaching $25-30 billion within the next five years. Emerging trends include increased adoption of subcutaneous immunoglobulin formulations offering improved patient convenience, development of recombinant and polyclonal alternatives, and growing interest in home-based administration models. Supply chain optimization, plasma collection technology advancements, and biosimilar development for certain immunoglobulin products may reshape competitive dynamics while supporting broader patient access to these essential therapies.

• •Subcutaneous and hyaluronidase-facilitated subcutaneous delivery methods gaining market share
• •Plasma collection expansion initiatives underway to address persistent supply-demand imbalances
• •Emerging market growth accelerating as local manufacturing capabilities and regulatory frameworks mature